Nabriva Therapeutics (NBRV) Reaches New 52-Week Low at $4.20

Nabriva Therapeutics PLC – (NASDAQ:NBRV) shares hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $4.20 and last traded at $4.39, with a volume of 8914 shares. The stock had previously closed at $4.29.

A number of brokerages have recently issued reports on NBRV. ValuEngine upgraded shares of Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 22nd. Cantor Fitzgerald set a $16.00 price target on shares of Nabriva Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 30th. Needham & Company LLC reiterated a “buy” rating and set a $18.00 price target on shares of Nabriva Therapeutics in a research note on Tuesday, May 8th. Wedbush reiterated an “outperform” rating on shares of Nabriva Therapeutics in a research note on Monday, March 19th. Finally, Northland Securities began coverage on shares of Nabriva Therapeutics in a research note on Thursday, May 31st. They set an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Nabriva Therapeutics currently has an average rating of “Buy” and a consensus price target of $16.81.

Get Nabriva Therapeutics alerts:

The stock has a market capitalization of $176.58 million, a price-to-earnings ratio of -1.54 and a beta of 1.74.

Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.23. Nabriva Therapeutics had a negative net margin of 600.34% and a negative return on equity of 79.30%. The company had revenue of $7.55 million for the quarter, compared to analyst estimates of $1.27 million. sell-side analysts expect that Nabriva Therapeutics PLC – will post -1.82 earnings per share for the current fiscal year.

In other Nabriva Therapeutics news, Director Stephen W. Webster purchased 8,000 shares of the stock in a transaction dated Wednesday, May 23rd. The shares were acquired at an average cost of $4.59 per share, for a total transaction of $36,720.00. Following the completion of the transaction, the director now directly owns 8,000 shares of the company’s stock, valued at $36,720. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel Robert Crotty purchased 10,000 shares of the stock in a transaction dated Wednesday, May 23rd. The stock was acquired at an average price of $4.48 per share, for a total transaction of $44,800.00. Following the completion of the transaction, the general counsel now directly owns 10,000 shares of the company’s stock, valued at $44,800. The disclosure for this purchase can be found here. Insiders have acquired 22,160 shares of company stock worth $100,596 over the last 90 days. 2.75% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in NBRV. DRW Securities LLC acquired a new stake in shares of Nabriva Therapeutics in the first quarter valued at approximately $106,000. JPMorgan Chase & Co. grew its position in shares of Nabriva Therapeutics by 163.9% in the first quarter. JPMorgan Chase & Co. now owns 24,959 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 15,501 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Nabriva Therapeutics in the first quarter valued at approximately $244,000. Virtu Financial LLC acquired a new stake in shares of Nabriva Therapeutics in the fourth quarter valued at approximately $429,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Nabriva Therapeutics by 173.2% in the first quarter. Dimensional Fund Advisors LP now owns 111,865 shares of the biotechnology company’s stock valued at $563,000 after purchasing an additional 70,917 shares during the last quarter. Institutional investors and hedge funds own 68.88% of the company’s stock.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Tesla Autopilot ��Nag Reduction Device�� Targeted by U.S. Agency

LISTEN TO ARTICLE 2:29 SHARE THIS ARTICLE Facebook Twitter LinkedIn Email

The Autopilot Buddy is marketed as a “nag reduction device” that can fool Tesla Inc.’s semi-autonomous driving system to circumvent a warning when a driver’s hands aren’t on the steering wheel, but U.S. regulators have another term for the product: “unacceptable.”

The U.S. National Highway Traffic Safety Administration on Tuesday said it was ordering the aftermarket device maker to cease selling the Autopilot Buddy because it could put drivers and others at risk.

A letter sent by NHTSA to the company, identified on the website autopilotbuddy.com as Dolder, Falco and Reese Partners LLC, orders it to respond by June 29 and certify that distribution and marketing of the product has ended. The company is not affiliated with Tesla.

The Autopilot Buddy website promises to reduce Tesla’s “nagging reminders” to drivers that they need to put their hands on the wheel in order to allow customers to "enjoy autopilot."

Despite those promises, NHTSA found the product “is intended to circumvent motor vehicle safety and driver attentiveness” NHTSA Deputy Administrator Heidi King said in a press release. “By preventing the safety system from warning the driver to return hands to the wheel, this product disables an important safeguard, and could put customers and other road users at risk.”

Just How Safe Is Driverless Car Technology, Really?: QuickTake

A Tesla spokesman said the company supports NHTSA’s action to force the company to end sales of the device.

While fully self-driving cars are still in development, several carmakers including Tesla and General Motors Co. have developed suites of technology that automatically keep cars in their lanes and follow the vehicle ahead at a safe distance.

The companies require drivers to keep their hands on the steering wheel, even if the cars are at times largely driving themselves. In the case of the Tesla, the system monitors steering wheel movements to assess whether the driver is engaged.

Despite the Autopilot Buddy website’s assertion that the hands-off warnings are an impediment to owners, it also maintains a disclaimer saying: "This is not intended to be a hands-off device, your hands must remain on the wheel as directed by Tesla’s terms of ‘Autosteer’ user agreement."

A spate of crashes involving Teslas has thrust the issue of semi-autonomous driving features into the news. The National Transportation Safety Board is looking at a March 23 accident in California in which the system didn’t detect the driver’s hands on the wheel when it struck a highway barrier and killed him.

Autopilot Buddy’s website currently discloses that it is no longer taking orders inside the U.S. Dolder, Falco and Reese is registered to Carl Reese in California. A phone message and email to Reese asking for comment were not immediately returned.

— With assistance by Alan Levin, and Ryan Beene

Navigator Holdings Ltd (NVGS) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Navigator Holdings Ltd (NYSE:NVGS) have earned a consensus recommendation of “Hold” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $15.00.

Several analysts recently weighed in on the company. ValuEngine raised Navigator from a “hold” rating to a “buy” rating in a research note on Thursday, May 31st. Maxim Group reiterated a “buy” rating and issued a $16.00 target price (up from $14.50) on shares of Navigator in a research report on Monday, March 5th. Finally, Zacks Investment Research upgraded Navigator from a “sell” rating to a “hold” rating in a research report on Tuesday, February 20th.

Get Navigator alerts:

A number of institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN grew its stake in Navigator by 218.9% during the fourth quarter. Wells Fargo & Company MN now owns 989,591 shares of the shipping company’s stock worth $9,748,000 after purchasing an additional 679,250 shares during the period. Penbrook Management LLC purchased a new position in Navigator during the fourth quarter worth about $1,481,000. Oppenheimer & Co. Inc. grew its position in Navigator by 2.4% during the first quarter. Oppenheimer & Co. Inc. now owns 1,577,539 shares of the shipping company’s stock worth $18,536,000 after buying an additional 37,460 shares in the last quarter. Frontier Capital Management Co. LLC grew its position in Navigator by 34.1% during the first quarter. Frontier Capital Management Co. LLC now owns 916,118 shares of the shipping company’s stock worth $10,764,000 after buying an additional 233,178 shares in the last quarter. Finally, BancorpSouth Bank purchased a new position in Navigator during the first quarter worth about $411,000. Hedge funds and other institutional investors own 68.70% of the company’s stock.

Shares of Navigator traded up $0.12, hitting $11.03, during mid-day trading on Monday, MarketBeat Ratings reports. The stock had a trading volume of 33,351 shares, compared to its average volume of 100,428. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.90 and a quick ratio of 0.82. Navigator has a 12-month low of $7.00 and a 12-month high of $13.25. The stock has a market cap of $605.30 million, a price-to-earnings ratio of 68.91, a price-to-earnings-growth ratio of 4.55 and a beta of 1.22.

Navigator (NYSE:NVGS) last released its earnings results on Wednesday, May 9th. The shipping company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.05). The company had revenue of $77.81 million for the quarter, compared to analyst estimates of $62.22 million. Navigator had a return on equity of 0.34% and a net margin of 1.09%. The business’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period last year, the company posted $0.05 earnings per share. equities analysts expect that Navigator will post 0.27 earnings per share for the current fiscal year.

About Navigator

Navigator Holdings Ltd. owns and operates a fleet of liquefied gas carriers worldwide. The company provides international and regional seaborne transportation services of liquefied petroleum gas, petrochemical gases, and ammonia for energy companies, industrial users, and commodity traders. As of December 31, 2017, it owned and operated a fleet of 38 vessels.

Acuity Brands, Inc. (AYI) Stake Boosted by BlackRock Inc.

BlackRock Inc. lifted its stake in shares of Acuity Brands, Inc. (NYSE:AYI) by 1.8% during the first quarter, HoldingsChannel.com reports. The firm owned 2,839,265 shares of the electronics maker’s stock after purchasing an additional 50,931 shares during the period. BlackRock Inc. owned 0.07% of Acuity Brands worth $395,201,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Glen Harbor Capital Management LLC grew its stake in shares of Acuity Brands by 11.4% during the 1st quarter. Glen Harbor Capital Management LLC now owns 4,658 shares of the electronics maker’s stock worth $648,000 after purchasing an additional 476 shares during the period. KBC Group NV grew its stake in shares of Acuity Brands by 861.7% during the 1st quarter. KBC Group NV now owns 87,448 shares of the electronics maker’s stock worth $12,171,000 after purchasing an additional 78,355 shares during the period. Eagle Asset Management Inc. grew its stake in shares of Acuity Brands by 6.1% during the 1st quarter. Eagle Asset Management Inc. now owns 481,724 shares of the electronics maker’s stock worth $67,051,000 after purchasing an additional 27,600 shares during the period. Korea Investment CORP grew its stake in shares of Acuity Brands by 53.5% during the 1st quarter. Korea Investment CORP now owns 31,006 shares of the electronics maker’s stock worth $4,316,000 after purchasing an additional 10,806 shares during the period. Finally, Penserra Capital Management LLC grew its stake in shares of Acuity Brands by 57.1% during the 1st quarter. Penserra Capital Management LLC now owns 1,650 shares of the electronics maker’s stock worth $214,000 after purchasing an additional 600 shares during the period.

Get Acuity Brands alerts:

AYI has been the topic of a number of recent analyst reports. ValuEngine cut shares of Acuity Brands from a “hold” rating to a “sell” rating in a research note on Monday, April 2nd. Roth Capital set a $105.00 price objective on shares of Acuity Brands and gave the company a “sell” rating in a research note on Monday, April 2nd. Robert W. Baird reissued a “hold” rating and issued a $168.00 price objective on shares of Acuity Brands in a research note on Friday, March 16th. Williams Capital lowered their price objective on shares of Acuity Brands from $175.00 to $151.00 and set a “hold” rating on the stock in a research note on Thursday, April 5th. Finally, JMP Securities raised shares of Acuity Brands from a “market perform” rating to an “outperform” rating and set a $150.00 price objective on the stock in a research note on Thursday, April 5th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the stock. Acuity Brands has a consensus rating of “Hold” and a consensus target price of $177.82.

Shares of Acuity Brands opened at $121.50 on Friday, according to MarketBeat Ratings. The stock has a market capitalization of $5.02 billion, a P/E ratio of 15.26, a price-to-earnings-growth ratio of 1.57 and a beta of 1.33. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.51 and a current ratio of 2.15. Acuity Brands, Inc. has a 52 week low of $109.98 and a 52 week high of $208.82.

Acuity Brands (NYSE:AYI) last released its earnings results on Wednesday, April 4th. The electronics maker reported $1.89 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.95 by ($0.06). The firm had revenue of $832.10 million during the quarter, compared to analysts’ expectations of $799.33 million. Acuity Brands had a net margin of 9.68% and a return on equity of 20.56%. Acuity Brands’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter last year, the company posted $1.77 earnings per share. equities research analysts expect that Acuity Brands, Inc. will post 7.99 earnings per share for the current year.

Acuity Brands declared that its board has initiated a share buyback plan on Wednesday, April 4th that permits the company to repurchase 6,000,000 outstanding shares. This repurchase authorization permits the electronics maker to purchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

In other news, Director W. Patrick Battle bought 1,330 shares of Acuity Brands stock in a transaction on Thursday, May 3rd. The shares were bought at an average cost of $112.91 per share, for a total transaction of $150,170.30. Following the acquisition, the director now owns 2,809 shares in the company, valued at $317,164.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director George Douglas Dillard, Jr. bought 5,000 shares of Acuity Brands stock in a transaction on Tuesday, May 8th. The stock was purchased at an average price of $112.76 per share, for a total transaction of $563,800.00. The disclosure for this purchase can be found here. 1.50% of the stock is currently owned by corporate insiders.

Acuity Brands Profile

Acuity Brands, Inc provides lighting and building management solutions and services for commercial, institutional, industrial, infrastructure, and residential applications in North America and internationally. The company offers lighting and controls products and solutions, such as recessed, surface, and suspended lighting; down, decorative, emergency and exit, track, day, special-use, street and roadway, parking garage, landscape, and underwater lighting; area pedestrian, flood, and decorative site lighting; occupancy sensors; photo controls; relay panels; architectural dimming panels; and integrated lighting controls systems.

Want to see what other hedge funds are holding AYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acuity Brands, Inc. (NYSE:AYI).